LPL Financial’s Trevi Therapeutics TRVI Stock Holding History

LPL Financial’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.18M	Sell	63,449 -17,434	-22%	-$254K	﹤0.01%	4282
2026 Q1	$965K	Buy	80,883 +27,923	+53%	+$313K	﹤0.01%	4213
2025 Q4	$663K	Buy	52,960 +12,510	+31%	+$145K	﹤0.01%	4460
2025 Q3	$370K	Buy	40,450 +28,550	+240%	+$214K	﹤0.01%	4877
2025 Q2	$65.1K	Buy	+11,900	New	+$74K	﹤0.01%	5336
2025 Q1	–	Sell	-36,000	Closed	-$148K	–	5519
2024 Q4	$148K	Hold	36,000	–	–	﹤0.01%	4899
2024 Q3	$120K	Hold	36,000	–	–	﹤0.01%	4858
2024 Q2	$107K	Hold	36,000	–	–	﹤0.01%	4731
2024 Q1	$124K	Buy	+36,000	New	+$80.3K	﹤0.01%	4632
2023 Q3	–	Sell	-10,000	Closed	-$23.9K	–	4795
2023 Q2	$23.9K	Hold	10,000	–	–	﹤0.01%	4503
2023 Q1	$18.5K	Hold	10,000	–	–	﹤0.01%	4418
2022 Q4	$19.3K	Sell	10,000 -10,000	-50%	-$19.7K	﹤0.01%	4372
2022 Q3	$31K	Buy	20,000 +10,000	+100%	+$32.8K	﹤0.01%	4288
2022 Q2	$28K	Hold	10,000	–	–	﹤0.01%	4306
2022 Q1	$22K	Hold	10,000	–	–	﹤0.01%	4119
2021 Q4	$8K	Hold	10,000	–	–	﹤0.01%	4326
2021 Q3	$14K	Hold	10,000	–	–	﹤0.01%	4307
2021 Q2	$23K	Hold	10,000	–	–	﹤0.01%	4188
2021 Q1	$27K	Hold	10,000	–	–	﹤0.01%	4035
2020 Q4	$24K	Hold	10,000	–	–	﹤0.01%	3774
2020 Q3	$40K	Hold	10,000	–	–	﹤0.01%	3452
2020 Q2	$66K	Buy	+10,000	New	+$35.2K	﹤0.01%	3334

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

LPL Financial's TRVI Position: Q2 2026 in Review

LPL Financial reduced its Trevi Therapeutics (TRVI) stake by 22% in Q2 2026, selling an estimated $254K and leaving 63,449 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #4282.

LPL Financial first reported a position in TRVI in Q2 2020 and has held it in 22 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

LPL Financial held 63,449 shares of Trevi Therapeutics worth $1.18M as of Q2 2026.
LPL Financial sold 17,434 Trevi Therapeutics shares in Q2 2026, an estimated $254K.
Trevi Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #4282 holding.
LPL Financial first reported a position in Trevi Therapeutics in Q2 2020 and has held it in 22 quarters since.
218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.